Literature DB >> 24085840

Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism.

Angelica M Merlot1, Namfon Pantarat, Sharleen V Menezes, Sumit Sahni, Des R Richardson, Danuta S Kalinowski.   

Abstract

The chelator di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) shows potent and selective anticancer and antimetastatic activity. However, the mechanism by which it is initially transported into cells to induce cytotoxicity is unknown. Hence, the current investigation examined the cellular uptake of ¹⁴C-Dp44mT relative to two structurally related ligands, namely the aroylhydrazone ¹⁴C-pyridoxal isonicotinoyl hydrazone (¹⁴C-PIH) and the thiosemicarbazone (¹⁴C-2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (¹⁴C-Bp4eT). In marked contrast to the cellular uptake of ¹⁴C-PIH and ¹⁴C-Bp4eT, which were linear as a function of concentration, ¹⁴C-Dp44mT uptake was saturable using SK-N-MC neuroepithelioma cells (Bmax, 4.28 × 10⁷ molecules of chelator/cell; and Kd, 2.45 μM). Together with the fact that ¹⁴C-Dp44mT uptake was temperature-dependent and significantly (P < 0.01) decreased by competing unlabeled Dp44mT, these observations indicated a saturable transport mechanism consistent with carrier/receptor-mediated transport. Other unlabeled ligands that shared the saturated N4 structural moiety with Dp44mT significantly (P < 0.01) inhibited ¹⁴C-Dp44mT uptake, illustrating its importance for carrier/receptor recognition. Nevertheless, unlabeled Dp44mT most markedly decreased (¹⁴C-Dp44mT uptake, demonstrating that the putative carrier/receptor shows high selectivity for Dp44mT. Interestingly, in contrast to ¹⁴C-Dp44mT, uptake of its Fe complex [Fe(¹⁴C-Dp44mT)₂] was not saturable as a function of concentration and was much greater than the ligand alone, indicating an alternate mode of transport. Studies examining the tissue distribution of ¹⁴C-Dp44mT injected intravenously into a mouse tumor model demonstrated the ¹⁴C label was primarily identified in the excretory system. Collectively, these findings examining the mechanism of Dp44mT uptake and its distribution and excretion have clinical implications for its bioavailability and uptake in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085840     DOI: 10.1124/mol.113.088393

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), an anticancer agent, exerts an anti-inflammatory effect in activated human mast cells.

Authors:  Sun-Young Nam; Na-Ra Han; Kyoung Wan Yoon; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Inflamm Res       Date:  2017-06-14       Impact factor: 4.575

2.  The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1.

Authors:  Wensheng Liu; Fei Yue; Minhua Zheng; Angelica Merlot; Dong-Hun Bae; Michael Huang; Darius Lane; Patric Jansson; Goldie Yuan Lam Lui; Vera Richardson; Sumit Sahni; Danuta Kalinowski; Zaklina Kovacevic; Des R Richardson
Journal:  Oncotarget       Date:  2015-04-20

3.  In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Authors:  Eliška Potůčková; Jaroslav Roh; Miloslav Macháček; Sumit Sahni; Ján Stariat; Vít Šesták; Hana Jansová; Pavlína Hašková; Anna Jirkovská; Kateřina Vávrová; Petra Kovaříková; Danuta S Kalinowski; Des R Richardson; Tomáš Šimůnek
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

4.  Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells.

Authors:  Angelica M Merlot; Sumit Sahni; Darius J R Lane; Ashleigh M Fordham; Namfon Pantarat; David E Hibbs; Vera Richardson; Munikumar R Doddareddy; Jennifer A Ong; Michael L H Huang; Des R Richardson; Danuta S Kalinowski
Journal:  Oncotarget       Date:  2015-04-30

5.  Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.

Authors:  Vit Sestak; Jan Stariat; Jolana Cermanova; Eliska Potuckova; Jaroslav Chladek; Jaroslav Roh; Jan Bures; Hana Jansova; Petr Prusa; Martin Sterba; Stanislav Micuda; Tomas Simunek; Danuta S Kalinowski; Des R Richardson; Petra Kovarikova
Journal:  Oncotarget       Date:  2015-12-15

6.  New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action.

Authors:  Kateryna Ohui; Eleonora Afanasenko; Felix Bacher; Rachel Lim Xue Ting; Ayesha Zafar; Núria Blanco-Cabra; Eduard Torrents; Orsolya Dömötör; Nóra V May; Denisa Darvasiova; Éva A Enyedy; Ana Popović-Bijelić; Jóhannes Reynisson; Peter Rapta; Maria V Babak; Giorgia Pastorin; Vladimir B Arion
Journal:  J Med Chem       Date:  2018-12-18       Impact factor: 7.446

Review 7.  Unraveling the mysteries of serum albumin-more than just a serum protein.

Authors:  Angelica M Merlot; Danuta S Kalinowski; Des R Richardson
Journal:  Front Physiol       Date:  2014-08-12       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.